Steven Reed

Steven Reed

Company: HDT Bio

Job title: Chief Executive Officer & Co-Founder


Panel Discussion: How can biotechs best leverage partnerships early on in drug development to ensure cancer vaccine success? 11:45 am

Assessing the importance of bringing in the right staff from the field Developing the science and the story in early development to attract potential partners, when you don’t have clinical data available Attributes of a perfect partnership Types of partnerships (in/out licensing of product, financing of clinical trial, providing comparator drug, etc.) Key partnerships crucial…Read more

day: Day Two

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4 + Th1 Responses and Potential Use as a Cancer Vaccine 3:15 pm

HER3 peptide-pulsed dendritic cell vaccination resulted in anti-HER3 CD4+ Th1 responses that prevented tumor development, significantly delayed tumor growth in prevention models, and caused regression in multiple therapeutic models of HER3-expressing murine tumors, including mammary carcinoma and melanoma Tumors were robustly infiltrated with CD4+ T cells, suggesting their key role in tumor rejection Data demonstrates…Read more

day: Pre-Conference Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.